RxDoctor Payments Data

Veneta Ianakieva, MD

Family Medicine · Albuquerque, NMNPI 1568805018

Payments from drug & device makers

$930in general payments, 2019–2025

Across 33 payments — averaging $28.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$277
  • Lilly USA, LLC$136
  • Astellas Pharma US Inc$108
  • Aimmune Therapeutics, Inc.$93
  • Biohaven Pharmaceuticals, Inc.$89
  • GSK$74
  • plus $153 from 6 others

What the payments were for

  • Food & beverage$930100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$930 in reported general payments places this provider in the 80th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$32,274
Medicare patients
153
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron82$67,778
FarxigaDapagliflozin Propanediol57$64,729
XareltoRivaroxaban61$60,012
MounjaroTirzepatide56$58,636
EliquisApixaban52$47,152
Spiriva RespimatTiotropium Bromide42$24,718
OzempicSemaglutide24$22,147
LinzessLinaclotide37$20,536
SymbicortBudesonide/Formoterol Fumarate70$20,462
JanuviaSitagliptin Phosphate16$13,866
TrintellixVortioxetine Hydrobromide18$13,388
CreonLipase/Protease/Amylase11$12,344
Arnuity ElliptaFluticasone Furoate49$11,358
TrulicityDulaglutide11$10,456
Levothyroxine Sodium616$9,244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$12$85,191127 claims
Lilly USA, LLCMounjaro, Trulicity$136$69,09167 claims
Astellas Pharma US IncMyrbetriq$108$67,77882 claims
PfizerEliquis$40$47,15252 claims
AbbVieLinzess, Creon, Synthroid$277$36,437112 claims
Novo NordiskOzempic$16$22,14724 claims
GSKArnuity Ellipta$74$11,35849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →